Composition for promoting proliferation of bacteria of genus blautia, method for proliferating bacteria of genus blautia, and method for producing bacteria of genus blautia

Abstract

The purpose of the present invention is to provide a novel composition for promoting the proliferation of bacteria of the genus Blautia, a medical treatment method based on promoting the proliferation of bacteria of the genus Blautia, a health promotion method based on promoting the proliferation of bacteria of the genus Blautia, and a method for producing or proliferating bacteria of the genus Blautia. The present invention provides: a composition, for promoting the proliferation of bacteria of the genus Blautia, comprising 2'-fucosyllactose or a salt thereof as an active ingredient; and a composition, for promoting the proliferation of bacteria of the genus Blautia, comprising 3'-sialyllactose or a salt thereof as an active ingredient.

Description

Composition for promoting the growth of Blautia bacteria, method for growing Blautia bacteria, and method for producing Blautia bacteria

[0001] The present invention relates to a composition for promoting the growth of bacteria of the genus Blautia, a method for growing bacteria of the genus Blautia, and a method for producing bacteria of the genus Blautia.

[0002] Blautia bacteria are butyrate-producing bacteria that are normally present in the human intestine (Non-Patent Document 1). Butyrate is one of the representative useful metabolites produced by intestinal bacteria, and has been reported to have various effects, such as improving diseases such as inflammatory bowel disease and colon cancer, as well as immune regulation and improving the intestinal barrier (Non-Patent Document 2). Blautia bacteria have also been reported to be associated with various diseases.

[0003] According to Non-Patent Document 3, people with low visceral fat area had higher Blautia bacteria in their intestines. According to Non-Patent Document 4, Blautia bacteria, particularly Blautia alti and Blautia wechselellae, were reduced in the intestines of obese children, and these two bacteria also exhibited anti-inflammatory effects in cultured cells. According to Non-Patent Document 5, oral administration of Blautia hansenii reduced the severity of colitis in a mouse model. According to Non-Patent Document 6, Blautia hominis was found to be low in the intestines of patients who developed postoperative delirium. According to Non-Patent Document 7, Blautia glycerol was found to be low in patients with Parkinson's disease. Therefore, promoting the growth of Blautia bacteria in the intestines is important for alleviating the symptoms of the above-mentioned diseases and maintaining health.

[0004] In recent years, human milk oligosaccharides (HMOs) contained in human breast milk have attracted attention as prebiotics that selectively act on beneficial intestinal bacteria. According to Patent Document 1 and Non-Patent Document 8, fucose and HMOs containing fucose as a constituent sugar promoted the growth of Blautia bacteria, particularly Blautia wechselellae. According to Non-Patent Document 9, when rats were given a high dose of a mixture of HMOs, 2'-fucosyllactose and 3'-sialyllactose, the number of Blautia bacteria increased. According to Non-Patent Document 10, when piglets were given a mixture of HMOs, 2'-fucosyllactose and lacto-N-neotetraose, the number of Blautia bacteria increased.

[0005] A pharmaceutical composition containing Blautia hydrogenotrophica and a specific HMO has been reported, but there is no description of the growth-promoting effect of the HMO on Blautia bacteria (Patent Document 2). It has been reported that sialylated HMOs increase the number of Blautia bacteria, but no specific HMOs or bacterial species are disclosed (Non-Patent Document 11). It has been reported that specific HMOs increase the number of Blautia bacteria, but no specific bacterial species are disclosed (Patent Document 3).

[0006] Except for Patent Document 1 and Non-Patent Document 8, there is no description of the growth-promoting effect of individual HMOs on bacteria of the genus Blautia or the specific species of bacteria of the genus Blautia. Therefore, it remains unclear which species of bacteria of the genus Blautia each individual HMO promotes the growth of.

[0007] Japanese Patent Application Publication No. 2022-80035 U.S. Patent No. 10,980,845 International Publication No. 2023 / 176950

[0008] Front Microbiol. 2021;12:660920. Front Microbiol. 2023 Jan 12:13:1103836. NPJ Biofilms Microbiomes. 2019;5:28. mSystems. 2020 Mar 24;5(2):e00857-19. Microbiome. 2022 Jun 14;10(1):91. Front Psychiatry. 2022;13:852269. Bull Exp Biol Med. 2017 Apr;162(6):734-737. Front Microbiol. 2022 Jun 2;13:913624. Obesity (Silver Spring). 2023 May; 31(5):1362-1375. Microorganisms. 2021 Apr 21;9(5):884. Danica Bajic et al., 14th Asian Congress of Nutrition (14th CAN 2023), Title: Health from the Gut: the influence of nutrition ingredients on the human microbiome

[0009] An object of the present disclosure is to provide a novel composition for promoting the growth of Blautia bacteria, a method for treatment by promoting the growth of Blautia bacteria, a method for promoting health by promoting the growth of Blautia bacteria, or a method for producing or growing Blautia bacteria.

[0010] The present inventors have discovered that a specific oligosaccharide or a salt thereof promotes the growth of a specific bacterium belonging to the genus Blautia, and have thus completed the present invention.

[0011] Therefore, the present disclosure provides the following [1] to

[13] . [1] A composition for promoting the growth of at least one Blautia bacterium selected from the group consisting of Blautia hansenii, Blautias dococcoides, Blautia glyceracea, Blautia alti, Blautia ammonilitica, and Blautia cinchi, comprising 2'-fucosyllactose or a salt thereof as an active ingredient. [2] The composition according to [1], wherein the Blautia bacterium is Blautia hansenii. [3] The composition according to [2], wherein the Blautia hansenii is Blautia hansenii JCM35484. [4] A composition for promoting the growth of at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautia algi, Blautias dococcoides, Blautia hominis, Blautia glyceracea, Blautia alti, and Blautia sincki, comprising 3'-sialyllactose or a salt thereof as an active ingredient. [5] The composition according to [4], wherein the bacterium of the genus Blautia is at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautias dococcoides, and Blautia hominis. [6] The composition according to [5], wherein the bacterium of the genus Blautia is Blautias dococcoides. [7] The composition according to any one of [1] to [6], which is a food or drink. [8] The composition according to any one of [1] to [6], which is a pharmaceutical or quasi-drug. [9] The composition according to any one of [1] to [8], which is administered or ingested after confirming that there is a high possibility that the effect of promoting the growth of the Blautia bacteria will be obtained in a human being to whom the composition is administered or ingested.

[10] A method for growing Blautia bacteria, comprising a step of allowing 2'-fucosyllactose or a salt thereof to act on at least one Blautia bacterium selected from the group consisting of Blautia hansenii, Blautias dococcoides, Blautia glyceracea, Blautia alti, Blautia ammonilitica, and Blautia cinchi.

[11] A method for growing bacteria of the genus Blautia, comprising a step of allowing 3'-sialyllactose or a salt thereof to act on at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautia algi, Blautias-dococcoides, Blautia hominis, Blautia gluceracea, Blautia alti, and Blautia schinki.

[12] A method for producing bacteria of the genus Blautia, comprising a step of allowing 2'-fucosyllactose or a salt thereof to act on at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautias-dococcoides, Blautia gluceracea, Blautia alti, Blautia ammonilitica, and Blautia schinki.

[13] A method for producing Blautia bacteria, comprising a step of allowing 3'-sialyllactose or a salt thereof to act on at least one Blautia bacterium selected from the group consisting of Blautia hansenii, Blautia algi, Blautias dococcoides, Blautia hominis, Blautia glyceracea, Blautia alti, and Blautia sincki.

[0012] The present disclosure also relates to the following aspects, which can be adopted by adding the above aspects [2] to

[13] to the following aspects. - Use of 2'-fucosyllactose or a salt thereof for producing a composition for promoting the growth of at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautias-dococcoides, Blautia gluceracea, Blautia alti, Blautia ammonilitica, and Blautia schinki. - Use of 3'-sialyllactose or a salt thereof for producing a composition for promoting the growth of at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautia algi, Blautias-dococcoides, Blautia hominis, Blautia gluceracea, Blautia alti, and Blautia schinki. 2'-Fucosyllactose or a salt thereof for use in promoting the growth of at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautias-dococcoides, Blautia gluceracea, Blautia alti, Blautia ammonilitica, and Blautia schinki. 3'-Sialyl lactose or a salt thereof for use in promoting the growth of at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautias-dococcoides, Blautia hominis, Blautia gluceracea, Blautia alti, and Blautia schinki. A method for treating a disease that can be treated by promoting the growth of at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautias-dococcoides, Blautia gluceracea, Blautia alti, Blautia ammonilitica, and Blautia schinki, or a health promotion method that provides an ameliorating effect, comprising the step of administering or ingesting 2'-fucosyllactose or a salt thereof.A method for treating a disease that can be treated by promoting the growth of at least one bacterium of the genus Blautia selected from the group consisting of Blautia hansenii, Blautias-dococcoides, Blautia hominis, Blautia gluceracea, Blautia alti, and Blautia schinki, or a health promotion method that provides an ameliorating effect, comprising the step of administering or ingesting 3'-sialyllactose or a salt thereof.

[0013] According to the present disclosure, it is possible to provide a composition for promoting the growth of specific bacteria of the genus Blautia, which contains a specific oligosaccharide or a salt thereof as an active ingredient, and to provide a method for treatment by promoting the growth of bacteria of the genus Blautia with the specific oligosaccharide or a salt thereof, a method for promoting health by promoting the growth of bacteria of the genus Blautia, or a method for producing or growing bacteria of the genus Blautia.

[0014] FIG. 1 shows the OD of the cultured strains after 24 hours of culture. ６００ FIG. 2 shows the OD of the cultured strain after 24 hours of cultivation. ６００ FIG. 3 shows the OD of the cultured strain after 24 hours of cultivation. ６００ FIG. 4 shows the OD of the cultured strain after 24 hours of cultivation. ６００ FIG. 5 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 6 shows the OD of the cultured strain after 24 hours of cultivation. ６００ Figure 7 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 8 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 9 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 10 shows the OD of the cultured strain after 24 hours of cultivation. ６００ FIG. 11 shows the OD of the cultured strain after 24 hours of culture. ６００ FIG. 12 shows the OD of the cultured strain after 24 hours of cultivation. ６００ FIG. 13 shows the OD of the cultured strain after 24 hours of cultivation. ６００ FIG. 14 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 15 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 16 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 17 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 18 shows the OD of the cultured strains after 24 hours of cultivation. ６００ FIG. 19 shows the OD of the cultured strains after 24 hours of cultivation. ６００ Shows.

[0015] The present disclosure relates to a composition for promoting the growth of specific bacteria of the genus Blautia, which comprises a specific oligosaccharide or a salt thereof as an active ingredient, a method for growing bacteria of the genus Blautia, which comprises acting on specific bacteria of the genus Blautia with the specific oligosaccharide or a salt thereof, and a method for producing bacteria of the genus Blautia, which comprises acting on specific bacteria of the genus Blautia with the specific oligosaccharide or a salt thereof. In the present disclosure, examples of oligosaccharides include 2'-fucosyllactose, 3'-sialyllactose, and 6'-sialyllactose.

[0016] In the present disclosure, "2'-fucosyllactose" is a compound in which the 2' position of lactose is substituted with a fucosyl group, and is also called 2'-O-fucosyllactose, 2'-FL, and its CAS number is 41263-94-9 (hereinafter also referred to as 2'-FL).

[0017] Furthermore, in the present disclosure, "3'-sialyllactose" refers to a compound in which the 3' position of lactose is substituted with a sialyl group, and is also called 3'-sialyl-D-lactose, 3'-N-acetylneuraminyllactose, or 3'-SL, and its CAS number is 35890-38-1 (hereinafter also referred to as 3'-SL).

[0018] Furthermore, in the present disclosure, "6'-sialyllactose" refers to a compound in which the 6' position of lactose is substituted with a sialyl group, and is also called 6'-sialyl-D-lactose, 6'-N-acetylneuraminyllactose, or 6'-SL, and its CAS number is 35890-39-2 (hereinafter also referred to as 6'-SL).

[0019] In the present disclosure, salts that can be formed by 2'-FL, 3'-SL, and 6'-SL include acid addition salts, metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, etc. Examples of acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate, and organic acid salts such as acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate, gluconate, and caprylate.

[0020] Examples of metal salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, zinc salts, etc. Examples of ammonium salts include ammonium and tetramethylammonium salts, etc.

[0021] Examples of organic amine addition salts include salts of morpholine and piperidine. Examples of amino acid addition salts include salts of glycine, phenylalanine, lysine, aspartic acid, and glutamic acid. Of the above salts, sodium salts of 3'-SL are preferred, but other salts or a suitable combination of two or more salts may also be used.

[0022] In this disclosure, an "active ingredient" refers to a component that exhibits the desired effect of its administration or ingestion, and the effect is the promotion of butyric acid production itself or is brought about by such promotion. For example, active ingredients in pharmaceuticals are administered to patients for the purpose of treating diseases, alleviating symptoms, or preventing recurrence, and the effect is described on the label or package insert. Similarly, active ingredients in health foods (including health functional foods, functional foods, nutrient functional foods, and foods for specified health uses) are ingested for the purpose of exerting a specific effect that is particularly useful for maintaining and improving the health of healthy individuals, and the effect is described on the packaging of the food.

[0023] In the present disclosure, "assimilation" means that a microorganism utilizes 2'-FL, 3'-SL, or 6'-SL as a nutrient source. This includes the proliferation of a microorganism by incorporating 2'-FL, 3'-SL, or 6'-SL directly or by degrading 2'-FL, 3'-SL, or 6'-SL into the microorganism. Whether an oligosaccharide is assimilated by a microorganism can be determined by whether the amount of 2'-FL, 3'-SL, or 6'-SL present before assimilation is reduced or disappeared after assimilation.

[0024] In the present disclosure, examples of Blautia bacteria include Blautia hansenii (B. hansenii), Blautia argi (B. argi), Blautia pseudococcoides (B. pseudococcoides), Blautia hominis (B. hominis), Blautia glucera (B. glucea), Blautia luti (B. luti), and Blautia ammonilitica (Blautia ammoniilytica: B. ammoniilytica), Blautia schinkii (B. schinkii), Blautia wexlerae (B. wexlerae), and the like.

[0025] The growth of Blautia bacteria includes an increase in the absolute number of the bacteria. The growth of Blautia bacteria can be confirmed, for example, by measuring the turbidity of a culture medium in which the bacteria are cultured, measuring the weight, measuring cell components such as adenosine triphosphate, measuring with a counting chamber, counting colonies by culture, or comparing the number of bacteria over time using a measurement kit for any of these.

[0026] Promoting the growth of Blautia bacteria means a change from a state in which no growth of Blautia bacteria is observed to a state in which growth of Blautia bacteria is observed, or a change from a state in which growth of Blautia bacteria is observed to a state in which the number of Blautia bacteria increases.

[0027] The degree of increase in the number of Blautia bacteria is not particularly limited as long as it is a significant increase compared to the number of bacteria when the composition of the present disclosure is not applied. In one aspect, however, the increase is preferably 25% or more, 50% or more, more preferably 100% or more, even more preferably 200% or more, 300% or more, and particularly preferably 400% or more, in the following order, compared to the number of bacteria when the composition of the present disclosure is not applied.

[0028] In another aspect, the degree of increase in the number of Blautia bacteria is preferably 40% or more, 60% or more, 80% or more, 100% or more, or 120% or more, in the following order, more preferably 150% or more, 200% or more, or 250% or more, even more preferably 300% or more, 350% or more, and particularly preferably 400% or more, relative to the number of the bacteria when the composition of the present disclosure is not applied. In another aspect, the degree of increase in the number of Blautia bacteria is preferably 100% or more relative to the number of the bacteria when the composition of the present disclosure is not applied.

[0029] In yet another aspect, the degree of increase in the number of Blautia bacteria is preferably 30% or more, more preferably 50% or more, greater than the number of bacteria when the composition of the present disclosure is applied to glucose.

[0030] In the present disclosure, the proliferation of Blautia bacteria, for example, through the production of short-chain fatty acids, can have an effect of improving diseases such as inflammatory bowel disease and colon cancer, as well as immune function and intestinal barrier function. Therefore, the present disclosure also provides a method for treating the above diseases that can be treated by promoting the proliferation of Blautia bacteria, and a health promotion method that can achieve the above-mentioned improving effects.

[0031] In the present disclosure, Blautia bacteria applicable to 2'-FL include Blautia hansenii, Blautias dococcoides, Blautia Glucellacea, Blautia alti, Blautia ammonilitica, and Blautia cinchi, preferably Blautia hansenii, more preferably Blautia hansenii JCM14655 or Blautia hansenii JCM35484, and even more preferably Blautia hansenii JCM35484.

[0032] In the present disclosure, Blautia bacteria applicable to 3'-SL include Blautia hansenii, Blautia algi, Blautias dococcoides, Blautia hominis, Blautia glucellacea, Blautia alti, and Blautia sincki, preferably Blautia hansenii, Blautias dococcoides, and Blautia hominis, and more preferably Blautias dococcoides.

[0033] In another embodiment of the present disclosure, the Blautia bacterium used for 3'-SL is Blautia wechslerae JCM 31267. In yet another embodiment, the Blautia bacterium used for 6'-SL is Blautia wechslerae JCM 31267.

[0034] The compositions of the present disclosure can be produced by adding 2'-FL, 3'-SL, or 6'-SL at any stage using conventional methods. In certain aspects of the present disclosure, the compositions can be formulated into formulations that are easy to administer or ingest. The dosage form may be any of oral preparations such as tablets, powders, granules, pills, suspensions, emulsions, infusions / decoctions, capsules, syrups, liquids, elixirs, extracts, tinctures, and liquid extracts, as well as parenteral preparations such as injections, infusions, creams, and suppositories, although oral preparations are preferred.

[0035] In one embodiment of the present disclosure, the composition is used as a food product. There are no limitations on the category or type of food, and examples include general foods and beverages, as well as foods for medical patients, health foods, functional foods, foods for specified health uses, dietary supplements, and dietary supplements.

[0036] In one aspect of the present disclosure, the composition is used as a general food or beverage. Examples of food or beverage products include various beverages, various foods, processed foods, liquid foods (such as soups), seasonings, nutritional drinks, confectioneries, and feed. As used herein, "processed foods" refers to natural ingredients (e.g., animals and plants) that have been processed and / or cooked. Examples of processed foods include processed meat products, processed vegetables, processed fruit products, frozen foods, retort foods, canned foods, bottled foods, and instant foods. Food or beverage products may also be provided in a sealed form in a bag or container, and any bag or container typically used for food can be used.

[0037] In the present disclosure, there are no particular limitations on the shape of the food, and the food may be in any food shape that is normally distributed, such as a solid (e.g., powder, granules, etc.), liquid, liquid food, jelly, tablet, granule, capsule, paste, suspension, etc. Foods can be produced using commonly known methods, and carbohydrates, proteins, lipids, dietary fiber, vitamins, biologically essential trace metals (e.g., manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), flavorings, etc. may be added.

[0038] In the present disclosure, the animal species to which the composition is administered or ingested and the animal species to which the treatment method or health promotion method is applied are not particularly limited, but are preferably mammals, more preferably humans. Furthermore, in another embodiment, the animal species to which the food is ingested and the animal species to which the health promotion method is applied are preferably healthy humans.

[0039] In the present disclosure, the person to whom the composition is administered or ingested and the person to whom the treatment method or health promotion method is applied are not limited by gender, age, race, country or region, etc., and may be any of adults, elderly people, children, infants, and newborns, and is preferably a person aged 10 years or older, more preferably a person aged 15 years or older, even more preferably a person aged 18 years or older, and particularly preferably a person aged 20 years or older.

[0040] In the present disclosure, the composition may be administered or ingested 1 to 3 times daily for at least one week, and this schedule may be repeated. The timing of administration or ingestion of the composition is not particularly limited, and may be, for example, before meals, after meals, between meals, or before bedtime.

[0041] The composition for promoting the growth of Blautia bacteria according to one embodiment can be administered or ingested orally or parenterally, but is preferably administered or ingested orally.

[0042] The content of 2'-FL, 3'-SL, 6'-SL or salts thereof in the growth-promoting composition for Blautia bacteria according to one embodiment is not particularly limited, but may be, for example, preferably 0.01% by mass to 100% by mass based on the total amount of the composition.

[0043] In the present disclosure, the daily administration or intake amount of 2'-FL, 3'-SL, 6'-SL or salts thereof to humans can be 0.1 to 25 g, and preferably 1 to 10 g, calculated as the free form of 2'-FL, 3'-SL, or 6'-SL.

[0044] In one aspect of the present disclosure, it is preferable that the composition be administered or ingested and the treatment or health promotion method be applied after confirming that the composition is likely to have the effect of promoting the growth of Blautia bacteria or the effect of promoting butyric acid production in a human to whom the composition is administered or ingested, or to a human to whom the treatment or health promotion method is applied. Confirmation of this possibility is based on, for example, the presence or absence of Blautia bacteria in the intestinal microflora, using a method similar to that for measuring the number of Blautia bacteria. Confirmation of this possibility may be performed before the start of a schedule for administering or ingesting the composition, during the schedule, or between repeated sessions of the schedule.

[0045] The present invention will be specifically explained below by way of examples, but the present invention is not limited to the following examples as long as it does not depart from the gist of the invention.

[0046] The medium used was YCFAG medium minus the sugar source and VFA mix (hereinafter referred to as YCFA-medium). To prepare YCFAG medium, the reagents listed in Tables 1 to 5 were mixed, and the pH was adjusted to 7.45±0.05 with 1 mol / L sodium hydroxide solution (Fujifilm Wako Pure Chemical Industries, Ltd.). After autoclaving, 1 mL / L of Vitamin solution II (Table 6) and 10 mL / L of Hemin solution (Table 7) were added.

[0047] The sugar sources used in the study were glucose, 2'-FL, 3'-SL, and 6'-SL. Glucose was purchased from Fujifilm Wako Pure Chemical Industries, Ltd. 2'-FL, 3'-SL, and 6'-SL were obtained from Kyowa Hakko Bio Co., Ltd. Each sugar source was added to YCFA medium to a final concentration of 5 g / L to prepare the test medium.

[0048]

[0049]

[0050]

[0051]

[0052]

[0053]

[0054]

[0055] From the RIKEN BioResource Research Center, we received Blautia hansenii JCM14655, Blautia hansenii JCM35484, Blautia algi JCM31394, Blautias dococcoides JCM35243, Blautia hominis JCM32276, Blautia glucellacea JCM17039, Blautia hydrogenotrophica JCM14656, Blautia aliquaris JCM34225, Blautia alti JCM17040, and Blautia hominis JCM32276. Blautia aobeum JCM31340, Blautia acetisignens JCM34803, Blautia ammonilitica JCM34802, Blautia caesimris JCM34498, Blautia producta JCM1471, Blautia cinchii JCM14657, Blautia wechselellae JCM31267, Blautia wechselellae JCM35486, Blautia coccoides JCM1395, and Blautia physic JCM17205 were purchased. A single colony of each strain was inoculated into YCFAG medium and cultured overnight at 37°C. The OD of the overnight culture of each strain was ６００ The results are shown in Table 8. Each test medium was inoculated with 1 / 40 of the overnight culture solution, and after culturing at 37°C for 24 hours, the OD ６００ All cultures were performed under anaerobic conditions.

[0056] OD of each cultured strain after 24 hours of culture ６００ ​​​The results are shown in Tables 9 to 27 and Figures 1 to 19. In Tables 9 to 27 and Figures 1 to 19, "*" indicates a significant difference (p<0.05, Dunnett's test) compared to the condition without added sugar. "**" indicates a significant difference (p<0.01, Dunnett's test) compared to the condition without added sugar. "##" indicates a significant difference (p<0.01, t-test) compared to the condition with added sugar and glucose.

[0057]

[0058]

[0059]

[0060]

[0061]

[0062]

[0063]

[0064]

[0065]

[0066]

[0067]

[0068]

[0069]

[0070]

[0071]

[0072]

[0073]

[0074]

[0075]

[0076]

[0077] As shown in Table 9 and Figure 1, Blautia hansenii JCM14655 showed significant growth in the presence of glucose, 2'-FL, and 3'-SL compared to the sugar-free medium. As shown in Table 10 and Figure 2, Blautia hansenii JCM35484 showed significant growth in the presence of glucose, 2'-FL, and 3'-SL compared to the sugar-free medium. Furthermore, significant growth was observed in the presence of 2'-FL compared to the presence of glucose. As shown in Table 11 and Figure 3, Blautia algi JCM31394 showed significant growth in the presence of glucose and 3'-SL compared to the sugar-free medium.

[0078] As shown in Table 12 and FIG. 4, Blautia dococcoides JCM35243 showed significant growth in the presence of glucose, 2'-FL, and 3'-SL compared to the sugar-free medium. Also, significant growth was observed in the presence of 3'-SL compared to the presence of glucose. As shown in Table 13 and FIG. 5, Blautia hominis JCM32276 showed significant growth in the presence of glucose and 3'-SL compared to the sugar-free medium. As shown in Table 14 and FIG. 6, Blautia glyceracea JCM17039 showed significant growth in the presence of glucose, 2'-FL, and 3'-SL compared to the sugar-free medium.

[0079] As shown in Table 17 and FIG. 9, Blautia alti JCM17040 showed significant growth in the presence of glucose, 2'-FL, and 3'-SL compared to the sugar-free medium. As shown in Table 20 and FIG. 12, Blautia ammoniilytica JCM34802 showed significant growth in the presence of glucose and 2'-FL compared to the sugar-free medium. As shown in Table 23 and FIG. 15, Blautia cinchii JCM14657 showed significant growth in the presence of glucose, 2'-FL, and 3'-SL compared to the sugar-free medium. As shown in Table 24 and FIG. 16, Blautia wechslerae JCM31267 showed significant growth in the presence of glucose, 2'-FL, 3'-SL, and 6'-SL compared to the sugar-free medium.

[0080] Although various embodiments have been described above with reference to the drawings, it goes without saying that the present invention is not limited to such examples. It is clear that a person skilled in the art can conceive of various modifications or alterations within the scope of the claims, and it is understood that these also naturally fall within the technical scope of the present invention. Furthermore, the components of the above-described embodiments may be combined in any manner without departing from the spirit of the invention.

[0081] This application is based on a Japanese patent application (Patent Application No. 2023-198275) filed on November 22, 2023, the contents of which are incorporated herein by reference.

Claims

1. A composition for promoting the growth of at least one species of Blautia bacteria selected from the group consisting of Blautia hansenii, Blautia dococcoides, Blautia glyceracea, Blautia alti, Blautia ammoniilytica and Blautia sincki, which contains 2'-fucosyllactose or a salt thereof as an active ingredient.

2. The composition according to claim 1, wherein the Blautia bacterium is Blautia hansenii.

3. The composition according to claim 2, wherein the Blautia hansenii is Blautia hansenii JCM35484.

4. A composition for promoting the growth of at least one species of Blautia bacteria selected from the group consisting of Blautia hansenii, Blautia algi, Blautias dococcoides, Blautia hominis, Blautia glyceracea, Blautia alti and Blautia sincki, which contains 3'-sialyllactose or a salt thereof as an active ingredient.

5. The composition according to claim 4, wherein the Blautia bacterium is at least one species of Blautia bacterium selected from the group consisting of Blautia hansenii, Blautia dococcoides, and Blautia hominis.

6. The composition according to claim 5, wherein the Blautia bacterium is Blautia dococcoides.

7. The composition according to any one of claims 1 to 6, which is a food or drink.

8. The composition according to any one of claims 1 to 6, which is a drug or quasi-drug.

9. The composition according to any one of claims 1 to 8, which is administered or ingested after confirming that there is a high possibility that the effect of promoting the proliferation of the Blautia bacteria will be obtained in a human to whom the composition is administered or ingested.

10. A method for growing Blautia bacteria, comprising a step of allowing 2'-fucosyllactose or a salt thereof to act on at least one species of Blautia bacteria selected from the group consisting of Blautia hansenii, Blautia dococcoides, Blautia glyceracea, Blautia alti, Blautia ammoniilytica and Blautia sincki.

11. A method for growing Blautia bacteria, comprising a step of allowing 3'-sialyllactose or a salt thereof to act on at least one species of Blautia bacteria selected from the group consisting of Blautia hansenii, Blautia algi, Blautias dococcoides, Blautia hominis, Blautia glyceracea, Blautia alti, and Blautia sincki.

12. A method for producing Blautia bacteria, comprising a step of allowing 2'-fucosyllactose or a salt thereof to act on at least one species of Blautia bacteria selected from the group consisting of Blautia hansenii, Blautia dococcoides, Blautia glyceracea, Blautia alti, Blautia ammoniilytica and Blautia sincki.

13. A method for producing Blautia bacteria, comprising a step of allowing 3'-sialyllactose or a salt thereof to act on at least one species of Blautia bacteria selected from the group consisting of Blautia hansenii, Blautia algi, Blautias dococcoides, Blautia hominis, Blautia glyceracea, Blautia alti, and Blautia sincki.

Images